ArticleFrontiers in oncology2026

Circulating tumor DNA molecular response as a complementary biomarker to RECIST in immune checkpoint inhibitor therapy: current evidence and future directions.

Jian Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.